Lonza Completes Tender Offer for Arch Chemicals

18 Oct 2011 --- Lonza also announced that it has commenced a subsequent offering period to acquire additional untendered shares of Arch Chemicals common stock.

Oct 18 2011 --- Lonza Group Ltd, one of the world’s leading suppliers to the life science industries, announced the successful completion of the previously announced tender offer by Lonza and its indirect, wholly-owned subsidiary LG Acquisition Corp. for all outstanding shares of common stock of Arch Chemicals, Inc. at a price of USD 47.20 per share in cash, without interest and less any required withholding taxes. The tender offer expired, as scheduled, at 12:00 midnight, New York City time, on Friday, 14 October 2011, and was not extended.

Lonza received by the US Federal Trade Commission early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (the “HSR Act”) on 14 October 2011. Early termination under the HSR Act satisfied the remaining antitrust condition necessary for the consummation of the tender offer. As previously announced, Lonza had already obtained required antitrust clearances from the competition authorities in France and Germany.

BNY Mellon Shareowner Services, the depository for the tender offer, has advised Lonza that, as of the expiration of the tender offer, a total of approximately 23,372,120 shares of Arch Chemicals common stock (including 2,703,910 shares subject to guaranteed delivery procedures) were validly tendered and not properly withdrawn, representing approximately 91.9% of the shares of Arch Chemicals common stock then outstanding. LG Acquisition Corp. has accepted for payment the shares validly tendered and not properly withdrawn in the tender offer.

Lonza also announced that it has commenced a subsequent offering period to acquire additional untendered shares of Arch Chemicals common stock. The subsequent offering period will expire at 12:00 midnight, New York City time, on Wednesday, 19 October 2011. During this subsequent offering period, holders of shares of Arch Chemicals common stock who did not previously tender their shares into the initial tender offer may do so, and LG Acquisition Corp. will immediately accept for payment any shares properly tendered, for the same consideration, without interest and less any required withholding taxes, paid in the initial offering period of the tender offer.

Procedures for tendering shares during the subsequent offering period are the same as during the initial offering period, except that (i) the guaranteed delivery procedures may not be used, (ii) shares tendered during the subsequent offering period may not be withdrawn and (iii) Arch Chemicals 401(k) plan participants must submit their completed, signed and dated instruction form to the tabulation agent not later than 11:59 p.m., New York City Time, on 17 October 2011.

As a result of the tenders and after receipt of those shares subject to guaranteed delivery procedures, Lonza will own more than 90 percent of the outstanding shares of Arch Chemicals common stock and expects to complete its acquisition of Arch Chemicals through a short-form merger without a vote or meeting of Arch Chemicals’ shareholders. Upon completion of the merger, Arch Chemicals will become an indirect wholly-owned subsidiary of Lonza. In the merger, each of the remaining shares of Arch Chemicals common stock will be converted into the right to receive the same $47.20 in cash per share, without interest, that was paid in the tender offer. The merger is expected to occur promptly after the completion of the subsequent offering period.

Promptly after the completion of the merger, Lonza intends to cause all shares of Arch Chemicals common stock to be delisted from the New York Stock Exchange (the “NYSE”). Upon completion of the merger, Arch Chemicals shares will cease to be traded on the NYSE and Arch Chemicals will no longer have reporting obligations under the Securities Exchange Act of 1934, as amended.

To contact our editorial team please email us at editorial@cnsmedia.com

Lonza

Collapse

Lonza is one of the world’s leading suppliers to the pharmaceutical, healthcare and life science industries.


In the nutrition sector, Lonza offers a portfolio of branded health ingredients:

Carnipure™ is high quality L-carnitine, a nutrient essential for energy metabolism. Extensive scientific research shows that Carnipure™ can play a beneficial role in many areas of health, such as sports nutrition, weight management, infant nutrition, male fertility, and pregnancy.

Made from naturally occurring microalgae, DHAid™ is a purely vegetarian source of omega-3 DHA. Health benefits of DHAid™ include the support of brain development and function as well as heart and eye health.

ResistAid™ is a natural proprietary immune support ingredient that is formulated to deliver triple action immune benefits year round. Made from North American larch trees, it consists of arabinogalactan and bioactive flavonoids, which have antioxidant capacity.

The Memree™ brand covers a line of products that contain high quality, soy-based phosphatidylserine. Phosphatidylserine is an important structural component of cell membranes and is found in concentrated amounts in brain cells. Products in the Memree™ line include MemreePS™ for cognitive health and MemreePlus™ for cognitive health, stress reduction and exercise recovery applications.

Lonza is the leading supplier of vitamin B3 in the form of Niacin and Niacinamide. Vitamin B3 is an essential vitamin needed for protein, carbohydrate and fat metabolism. Additionally, Niacin has been shown to support healthy levels of HDL. Vitamin B3 is widely used in dietary supplements and functional foods and beverages.

 

Related Articles

Nutrition & Health News

Bone and joint health: Consumer demands and promising ingredients

19 Apr 2018 --- Mobility, which incorporates bone and joint health, is becoming a key concern for a range of demographics. NutritionInsight spoke with a number of key suppliers in the bone and joint health space about the key ingredients to look out for, as well as some key consumer demands driving innovation in this space.

Business News

Lonza to expand Florida encapsulation capabilities amid product development acceleration

21 Feb 2018 --- Swiss multinational, chemicals and biotechnology company, the Lonza Group is planning to expand its late-stage clinical and commercial encapsulation capabilities for solid oral and inhaled dosage forms in North America. The company will install a new Harro Hӧfliger Modu-C MS encapsulation unit (Harro unit) at its integrated product development and manufacturing facility in Tampa, Florida, to strengthen production and bring its products to market faster. 

Nutrition & Health News

L-Carnitine – "Unquestionable" room for market growth: Lonza

08 Feb 2018 --- From facilitating the recovery process in the sports nutrition sector to improving energy metabolism in healthy aging products, L-Carnitine has proven itself a versatile ingredient with the potential to be applied in myriad applications. “Sports nutrition, weight management, all these areas are still growing. There is no question that there is a lot of room for L-Carnitine’s development. We see a lot of demand coming from Asia and Africa for infant food applications. The other big market is for sure energy drinks,” Marco Gossen, Business Development Manager at Lonza, explains during a NutritionInsight webinar last week, looking at product development and untapped opportunities for L-Carnitine.

Business News

Capsugel acquisition boosts Lonza's “record-breaking” 2017 full-year results

31 Jan 2018 --- Swiss multinational, chemicals and biotechnology company, Lonza has exceeded 2017 earning expectations with robust sales and profit growth that is partly down to acquiring Capsugel last summer. Having closed the acquisition on 5 July 2017, Lonza consolidated Capsugel for nearly six months last year, which the company says strengthens its positions as a world leader in pharmaceutical, biotech and specialty ingredients markets. And now Lonza announces it’s “record-breaking” full-year results, hailing 2017 as a “major transformational year” for the company. 

Regulatory News

EFSA rejects Unilever black tea health claim

18 Jan 2018 --- The European Food and Safety Authority (EFSA) has rejected a health claim regarding black tea’s effects on the maintenance of normal endothelium-dependent vasodilation in adults. The application, submitted for authorization of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 by Unilever, pertained to “black tea beverages, either freshly prepared or reconstituted from water extract powders of black tea, characterized by the content of flavanols (expressed as catechins plus theaflavins) of at least 30 mg per 200 ml serving.” 

More Articles
URL : http://www.nutritioninsight.com:80/news/Lonza-Completes-Tender-Offer-for-Arch-Chemicals.html